G Vijuk1, A S Coates. 1. Sydney Melanoma Unit, Royal Prince Alfred Hospital, Australia.
Abstract
BACKGROUND: Malignant melanoma presents as metastatic disease without an apparent primary in about 4% of cases. These are referred to as occult primary melanoma (OPM). It is not known whether these represent de novo malignant transformation in non-cutaneous sites or the disappearance of an unrecognised primary, perhaps on an immunological basis. We hypothesised that OPM might have a superior prognosis compared to patients with similar disease extent from a known primary lesion (KPM). PATIENTS AND METHODS: We performed a retrospective cohort survival study of 146 patients with OPM and visceral metastases treated at the Sydney Melanoma Unit between 1983 and 1996. A control group of patients with KPM was matched for age, sex and site of visceral metastases. Survival was measured from the date of diagnosis of visceral metastases. RESULTS: Patients with OPM had a median survival of 233 days, significantly longer than the 176 days for those with KPM (P = 0.024; logrank test). Multivariate analysis allowing for simultaneous or prior involvement of lymph nodes, subcutaneous tissues or bone, and site of visceral involvement showed a significantly superior survival for OPM (hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.55-0.93). A small part of the effect was explained by treatment, but models allowing for this still showed a significantly longer survival. CONCLUSIONS: Survival was longer in OPM patients. This may reflect an intrinsically superior host-tumour interaction.
BACKGROUND:Malignant melanoma presents as metastatic disease without an apparent primary in about 4% of cases. These are referred to as occult primary melanoma (OPM). It is not known whether these represent de novo malignant transformation in non-cutaneous sites or the disappearance of an unrecognised primary, perhaps on an immunological basis. We hypothesised that OPM might have a superior prognosis compared to patients with similar disease extent from a known primary lesion (KPM). PATIENTS AND METHODS: We performed a retrospective cohort survival study of 146 patients with OPM and visceral metastases treated at the Sydney Melanoma Unit between 1983 and 1996. A control group of patients with KPM was matched for age, sex and site of visceral metastases. Survival was measured from the date of diagnosis of visceral metastases. RESULTS:Patients with OPM had a median survival of 233 days, significantly longer than the 176 days for those with KPM (P = 0.024; logrank test). Multivariate analysis allowing for simultaneous or prior involvement of lymph nodes, subcutaneous tissues or bone, and site of visceral involvement showed a significantly superior survival for OPM (hazard ratio (HR): 0.72; 95% confidence interval (CI): 0.55-0.93). A small part of the effect was explained by treatment, but models allowing for this still showed a significantly longer survival. CONCLUSIONS: Survival was longer in OPM patients. This may reflect an intrinsically superior host-tumour interaction.
Authors: Jatinder Goyal; Evan J Lipson; Neda Rezaee; Barish H Edil; Rich Schulick; Christopher L Wolfgang; Ralph H Hruban; Emmanuel S Antonarakis Journal: J Gastrointest Cancer Date: 2012-09
Authors: Jeffrey F Scott; Ruzica Z Conic; Cheryl L Thompson; Meg R Gerstenblith; Jeremy S Bordeaux Journal: J Am Acad Dermatol Date: 2018-03-23 Impact factor: 11.527
Authors: Deborah Kuk; Alexander N Shoushtari; Christopher A Barker; Katherine S Panageas; Rodrigo R Munhoz; Parisa Momtaz; Charlotte E Ariyan; Mary Sue Brady; Daniel G Coit; Kita Bogatch; Margaret K Callahan; Jedd D Wolchok; Richard D Carvajal; Michael A Postow Journal: Oncologist Date: 2016-06-10
Authors: Bożena Cybulska-Stopa; Marta Skoczek; Marek Ziobro; Tomasz Switaj; Sławomir Falkowski; Tadeusz Morysiński; Marcin Hetnał; Ida Cedrych; Piotr Rutkowski Journal: Contemp Oncol (Pozn) Date: 2013-01-04
Authors: Anna Doubrovsky; Richard A Scolyer; Rajmohan Murali; Paul R McKenzie; Geoffrey F Watson; C Soon Lee; Duncan J McLeod; William H McCarthy; Roger F Uren; Jonathan R Stretch; Robyn P Saw; John F Thompson Journal: Ann Surg Oncol Date: 2007-11-08 Impact factor: 5.344